The Bull Case For HealthEquity (HQY) Could Change Following Raised Earnings Outlook And Completed Buyback Program
HealthEquity (HQY) reported strong first-quarter revenue and net income, alongside raising its full-year fiscal 2027 earnings outlook and completing a significant share repurchase program. This positive update reinforces the company's investment narrative, which is built on the long-term value of Health Savings Accounts (HSAs) and the company's operational efficiencies. However, the company remains sensitive to interest income and potential competition in the HSA market.
One in Three Americans Delay Medical Care Due to Cost, HealthEquity Research Finds
A new study by HealthEquity, Inc. reveals that over one in three Americans delay or avoid medical care due to cost, leading to significant productivity losses in the workplace. The research indicates that while benefit understanding has increased, financial preparedness for healthcare expenses has decreased. However, individuals with Health Savings Accounts (HSAs) show stronger financial readiness and greater control over their healthcare costs, suggesting HSAs are a key factor in improving financial security related to health.
One in Three Americans Delay Medical Care Due to Cost, HealthEquity Research Finds
A new HealthEquity study reveals that over one-third of Americans delay or avoid medical care due to cost, impacting chronic condition patients, lower-income households, and younger workers disproportionately. This deferral of care leads to worsening health problems and significant workforce productivity losses for employers. The research highlights that Health Savings Account (HSA) holders exhibit stronger financial preparedness and control over healthcare costs compared to non-HSA individuals.
1 in 3 Americans delay care for cost; workers lose 7.3 hours weekly
A HealthEquity study reveals that 36% of Americans delayed or skipped medical care in the last six months due to cost, leading to significant productivity losses in the workplace, averaging 7.3 hours weekly per employee. The research highlights that Health Savings Account (HSA) holders exhibit greater financial preparedness and control over healthcare expenses compared to their non-HSA counterparts. HealthEquity emphasizes the critical role of HSAs in improving financial resilience for healthcare costs, especially for employers seeking to mitigate productivity losses stemming from employee financial stress.
What HealthEquity (HQY)'s Strong Q1, Higher Guidance and Buybacks Mean For Shareholders
HealthEquity (HQY) reported strong Q1 2026 results with revenue of US$354.64 million and net income of US$69.42 million. The company also raised its full-year revenue and earnings guidance for FY2027 and completed a US$244.45 million share repurchase program. These updates reinforce the investment narrative centered on the growth of health savings accounts, though investors should consider the sensitivity of earnings to interest income on custodial cash.
Norges Bank Buys New Shares in HealthEquity, Inc. $HQY
Norges Bank acquired a new stake in HealthEquity, Inc. (NASDAQ:HQY) during the fourth quarter, purchasing 730,567 shares valued at approximately $66.9 million. Despite this institutional buying, key insiders, including Director Gayle Furgurson Wellborn and EVP Michael Henry Fiore, have recently sold shares. HealthEquity reported strong quarterly results, exceeding analyst expectations for both EPS and revenue, with Wall Street maintaining a "Moderate Buy" rating and an average price target of $110.57.
Cost of goods sold of HealthEquity Inc – XETR:2HE
This page from TradingView provides financial information specifically on the "Cost of goods sold" for HealthEquity Inc, identified by its XETR stock symbol 2HE. The article appears to be a stub or a section of a larger financial data presentation, indicating where users can find this particular financial metric for the company. It lists the period, value, change, and percentage change.
Number of shareholders of HealthEquity, Inc. – NASDAQ:HQY
This page provides information on the number of shareholders for HealthEquity, Inc. (NASDAQ: HQY). It references market data from ICE Data Services and FactSet, along with SEC filings from Quartr. The content mainly consists of navigation links and disclaimers from TradingView.
Asset turnover of HealthEquity Inc – XETR:2HE
The article, titled "Asset turnover of HealthEquity Inc – XETR:2HE," focuses on financial data for HealthEquity Inc. It indicates that the company's asset turnover details are available for review, likely on the TradingView platform where the content originated. The primary content consists of navigational elements and data sourcing information, with the actual asset turnover value left blank.
HealthEquity Inc Cash Flow – XETR:2HE
This article provides key cash flow data for HealthEquity Inc (XETR:2HE). As of Q1 2026, the company's free cash flow is 82.83 million EUR, with the full year 2025 showing 384.10 million EUR in free cash flow and 385.77 million EUR in operating cash flow. The report details operating, investing, and financing activities through annual and quarterly metrics in EUR.
Westfield Capital Management Co. LP Raises Position in HealthEquity, Inc. $HQY
Westfield Capital Management Co. LP increased its stake in HealthEquity, Inc. by 13.7% in the fourth quarter, bringing its total holdings to 1,952,452 shares valued at approximately $178.9 million. This increase follows HealthEquity's strong financial performance, which included beating earnings expectations with $1.24 EPS and a 7.2% year-over-year revenue increase to $354.64 million. Despite recent insider selling, analysts maintain a "Moderate Buy" rating for the stock, with an average price target of $110.57.
(HQY) as a Liquidity Pulse for Institutional Tactics
This article provides an "AI Generated Signal" analysis for Healthequity Inc. (NYSE: HQY), highlighting a near-term weak sentiment that could test mid-term strength within a broader long-term weak bias. It outlines three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strengths, support, and resistance levels for institutional trading tactics.
RBC Capital reiterates HealthEquity stock rating on growth outlook By Investing.com
RBC Capital has reiterated an Outperform rating and a $108.00 price target for HealthEquity (NASDAQ:HQY), citing increased confidence in the company's growth and margin opportunities. The firm highlights HealthEquity's transformation into a digital platform and its potential to return to double-digit growth, supported by investments in automation and AI. This positive outlook is further bolstered by HealthEquity's strong Q1 FY27 financial results and a recent price target increase from Citizens.
HealthEquity Inc (HQY) Shares Fall 3.5% -- What GF Score of 92 T
HealthEquity Inc (HQY) shares recently fell 3.5% to $85.21, but GuruFocus indicates the stock is Modestly Undervalued with a GF Value™ of $101.63 and a strong GF Score™ of 92 out of 100. Despite its undervaluation and high growth/valuation ranks, investors are cautioned by a 4/10 momentum score and recent insider selling totaling $1.2 million with no buying activity. The company's P/E ratio of 34.6x is significantly below its 5-year median, further suggesting undervaluation.
HealthEquity (NASDAQ: HQY) EVP Fiore sells 3,142 shares under 10b5-1 plan
Michael Henry Fiore, EVP and Chief Commercial Officer of HealthEquity (NASDAQ: HQY), sold 3,142 shares of company stock at $95.00 per share, totaling $298,490. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. After the sale, Fiore directly holds 59,113 shares of HealthEquity.
RBC Capital reiterates HealthEquity stock rating on growth outlook
RBC Capital has reaffirmed its Outperform rating and $108.00 price target for HealthEquity (NASDAQ: HQY) following investor meetings, expressing increased confidence in the company's growth and margin potential. The firm believes HealthEquity's transformation into a digital platform with multiple monetization avenues will drive a return to double-digit growth. HealthEquity recently reported strong Q1 fiscal year 2027 results, surpassing market expectations, and analysts anticipate further margin expansion through automation and AI investments.
Legal & General Group Plc Lowers Stake in HealthEquity, Inc. $HQY
Legal & General Group Plc decreased its stake in HealthEquity, Inc. (NASDAQ:HQY) by 14.2% in the fourth quarter, selling 22,310 shares and retaining 135,356 shares valued at $12.4 million. Despite executive share sales, analysts maintain a "Moderate Buy" consensus with an average price target of $111.53, following strong quarterly results where HealthEquity reported EPS of $1.24 against an estimated $1.11 and revenue of $354.64 million. The company reported revenue growth of 7.2% year-over-year and has provided positive FY 2027 EPS guidance.
Healthequity Insider Sold Shares Worth $298,490, According to a Recent SEC Filing
An insider at HealthEquity (HQY) sold shares valued at $298,490, as reported in a recent SEC filing. This news comes amidst other recent updates for the company, including upgraded price targets from Deutsche Bank and RBC, and a strong Q1 earnings beat attributed to HSA growth and AI efficiency. The article also provides a brief company profile and lists recent analyst actions regarding HealthEquity.
HealthEquity director Wellborn Gayle Furgurson sells $219,510 in stock
HealthEquity director Wellborn Gayle Furgurson sold $219,510 worth of common stock on May 28, 2026, after exercising stock options. This transaction was part of a Rule 10b5-1 trading plan. Despite the director's sale, recent company news includes strong Q1 FY27 financial results, exceeding market expectations, and a raised price target from Citizens analysts, indicating a positive outlook for HealthEquity.
HealthEquity (NASDAQ: HQY) EVP Ladd sells 7,500 shares in open-market trade
HealthEquity's EVP and General Counsel, Delano Ladd, sold 7,500 shares of common stock at $90.00 per share in an open-market transaction on May 28, 2026. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2025. Following the transaction, Mr. Ladd directly holds 91,141 shares of HealthEquity.
HealthEquity (HQY) director sells 2,439 shares in 10b5-1 trade
HealthEquity director Gayle Furgurson sold 2,439 shares of common stock at $90.00 per share after exercising stock options for the same number of shares at $47.21 per share. These transactions, which netted approximately $220,000, were conducted on May 28, 2026, under a pre-arranged Rule 10b5-1 trading plan established on January 14, 2026. Following these trades, Furgurson directly holds 19,733 shares of HealthEquity.
Deutsche Bank Raises HealthEquity Price Target to $135 From $128, Maintains Buy Rating
Deutsche Bank has increased its price target for HealthEquity (HQY) to $135 from $128, while reaffirming a Buy rating on the stock. This adjustment suggests a positive outlook on the company's future performance by the investment bank.
Citizens raises HealthEquity stock price target to $111 on margin outlook
Citizens has increased its price target for HealthEquity (NASDAQ: HQY) to $111 from $110, maintaining a Market Outperform rating. This adjustment is based on an improved fiscal 2027 EBITDA margin assumption and higher non-GAAP earnings per share estimates for fiscal years 2027 and 2028. The firm anticipates continued share gains for HealthEquity due to its platform, partnerships, and market expansion opportunities.
HealthEquity, Inc. Stock 12‑Month Price Target Raised to $114.56, Implies 27% Upside
HealthEquity, Inc.'s average 12-month price target has increased to $114.56 from $113, with analysts forecasting a range of $88 to $135 per share. Based on the May 28 closing price, this new target suggests a potential 27% upside for the stock. The consensus rating from 17 analysts remains a "Buy."
HealthEquity, Inc. $HQY Position Increased by Future Fund LLC
Future Fund LLC significantly increased its stake in HealthEquity, Inc. (NASDAQ:HQY), boosting its holdings by 40.9% to 44,317 shares valued at $4.06 million in the fourth quarter. This increase follows HealthEquity's strong Q1 FY27 results, where it surpassed analyst EPS and revenue estimates and raised its full-year guidance. Analysts maintain a "Moderate Buy" rating with an average target price of $112.36, reflecting positive sentiment around the company's financial performance and strategic moves like expanding its share repurchase authorization.
HQY Stock News Today | Earnings, Events & Price Alerts
This article provides recent news, events, and price alerts for HQY stock (HealthEquity). It highlights HealthEquity's significant revenue growth and strong Q1 results, exceeding expectations and leading to raised guidance. The report also includes broader market updates, other companies' earnings, and Wall Street analyst calls.
HealthEquity Reports First Quarter Ended April 30, 2026 Financial Results; Raises Guidance
HealthEquity, Inc. announced strong financial results for its first quarter ended April 30, 2026, with net income up 29% to $69.4 million and Adjusted EBITDA increasing 17% to $164.5 million. The company raised its fiscal year 2027 guidance, projecting revenues between $1.410 billion and $1.420 billion, and authorized an additional $1.0 billion for its share repurchase program, reflecting confidence in its long-term growth and cash generation. Total HSA Assets grew 19% year-over-year to $37.1 billion.
How Investors May Respond To HealthEquity (HQY) Upgraded Outlook, AI Efficiencies and Larger Buyback Plan
HealthEquity (HQY) has reported strong first-quarter fiscal 2027 results with increased revenue and net income, leading management to raise full-year guidance and expand its share repurchase program. The company attributes these positive developments to AI-driven efficiency gains and technology investments, reinforcing its investment narrative focused on HSA adoption and resilient earnings. While the outlook is positive, the company's sensitivity to interest income and employment trends remains a key risk for investors.
HealthEquity Q1 2026 EPS Tops Expectations by 11.7%, Revenue Up 7%
HealthEquity, Inc. (NASDAQ:HQY) reported strong Q1 2026 results, with non-GAAP earnings of $1.24 per share, exceeding consensus by 11.7%, and revenue rising 7% year-over-year to $354.6 million, beating estimates. The company demonstrated robust operational performance driven by account growth, with total HSAs reaching 10.6 million and total HSA assets climbing to $37.11 billion. Management provided optimistic Fiscal Year 2027 guidance, projecting GAAP EPS between $2.88 to $2.95 and revenue of $1.41 billion to $1.42 billion, which was met with broad bullish sentiment from Wall Street analysts.
RBC Raises Price Target on HealthEquity to $108 From $100, Keeps Outperform Rating
RBC Capital Markets has increased its price target for HealthEquity (HQY) to $108 from $100, while maintaining an Outperform rating on the stock. This adjustment reflects RBC's positive outlook on the company's future performance.
HealthEquity on deck: Can Bronze HSA expansion fuel earnings?
HealthEquity Inc. is set to release its first-quarter fiscal 2027 results, with investors keenly focused on how new federal legislation expanding HSA eligibility to Bronze and Catastrophic health plans is impacting member growth. Analysts predict strong earnings and revenue growth, driven by an estimated 7.3 million newly eligible Americans. The company's recent strong performance and market dominance position it well to capitalize on these regulatory tailwinds.
HealthEquity (NASDAQ: HQY) boosts earnings as HSA assets and yields climb
HealthEquity, Inc. (NASDAQ: HQY) reported a 7% increase in quarterly revenue to $354.6 million and a 29% rise in net income to $69.4 million, driven by an 11% increase in custodial revenue and growth in service and interchange revenue. The company saw an 18% increase in HSAs with investments and a 19% increase in total HSA Assets to $37.1 billion, with the average annualized yield on HSA cash rising to 3.84%. HealthEquity also repurchased $123.0 million of its common stock and announced an additional $1.0 billion share repurchase authorization.
HealthEquity Reports First Quarter Ended April 30, 2026 Financial Results; Raises Guidance
HealthEquity, Inc. announced strong financial results for its first quarter ended April 30, 2026, with revenue increasing by 7% to $354.6 million and net income rising 29% to $69.4 million. The company also increased its share repurchase program by an additional $1.0 billion and raised its fiscal year 2027 guidance, anticipating revenues between $1.410 billion and $1.420 billion and Adjusted EBITDA of $625 million to $633 million. These results reflect continued growth in HSA accounts and assets, with total HSA assets reaching $37.1 billion, an increase of 19% year-over-year.
HealthEquity (HQY) Releases Q1 2027 Earnings: Revenue and Gross Profit Rise, EPS Miss
HealthEquity (HQY) reported Q1 2027 earnings with a revenue of $354.6 million, up 7.2% year-over-year but slightly missing analyst estimates, and a gross profit increase of 14.3% YoY. However, diluted EPS came in at $0.82, below the estimated $1.13. Despite the EPS miss, the company showed strong operating profit growth and margin improvement, with insider selling and varied institutional investor activity also noted.
HealthEquity: Fiscal Q1 Earnings Snapshot
HealthEquity Inc. reported strong fiscal first-quarter results, with net income reaching $69.4 million, or 82 cents per share. Adjusted earnings of $1.24 per share surpassed Wall Street estimates. The company also exceeded revenue forecasts and provided optimistic full-year earnings and revenue guidance.
Earnings Flash (HQY) HealthEquity, Inc. Reports Q1 Revenue $354.6M, vs. FactSet Est of $352.0M
HealthEquity, Inc. (HQY) reported its Q1 revenue of $354.6 million, surpassing the FactSet estimate of $352.0 million. The company also provided fiscal year 2027 guidance, expecting adjusted EPS in the range of $4.66 - $4.73 and revenue between $1.41 billion and $1.42 billion, both largely in line with or slightly above analyst expectations.
HealthEquity (NASDAQ: HQY) grows Q1 profit and adds $1B to buybacks
HealthEquity (NASDAQ: HQY) reported a strong Q1 for fiscal year 2027, with net income rising 29% to $69.4 million and revenue up 7% to $354.6 million. The company also announced a significant expansion of its share repurchase program, with an additional $1 billion authorized for future buybacks. HealthEquity raised its full-year guidance, projecting revenue between $1.410 billion and $1.420 billion and adjusted EBITDA of $625 million to $633 million.
[144] HEALTHEQUITY, INC. SEC Filing
This article reports on a Form 144 SEC filing by HealthEquity, Inc. (HQY) on May 28, 2026, indicating a proposed sale of 7,500 shares of common stock with an aggregate market value of $649,200.00. The shares were acquired through Restricted Stock Units on October 1, 2023, and are intended to be sold via Morgan Stanley Smith Barney LLC on NASDAQ. The filing includes standard disclosures about insider sales and a statement that the filer is unaware of material adverse information not publicly disclosed.
HealthEquity Reports First Quarter Ended April 30, 2026 Financial Results; Raises Guidance
HealthEquity, Inc. announced strong financial results for its first quarter ended April 30, 2026, with net income up 29% to $69.4 million and Adjusted EBITDA increasing 17% to $164.5 million. The company also reported a 7% increase in revenue to $354.6 million and significant growth in total HSA assets, which rose 19% to $37.1 billion. Reflecting confidence in its future, HealthEquity raised its guidance for fiscal year 2027 and authorized an additional $1.0 billion for its common stock repurchase program.
HEALTHEQUITY, INC. 1Q 2027: Revenue $354.64M, EPS $0.82— 10-Q Summary
HEALTHEQUITY, INC. (HQY) reported strong financial results for the first quarter of 2027, with revenue reaching $354.64 million and diluted EPS of $0.82. This outcome signifies year-over-year growth in both top-line and earnings, primarily fueled by increased custodial revenue and significant account expansion. The company saw a 7.2% rise in revenue, a 28.8% increase in net income, and a 34.4% boost in diluted EPS compared to the prior year.
HealthEquity Reports First Quarter Ended April 30, 2026 Financial Results; Raises Guidance
HealthEquity, Inc. announced strong financial results for its first quarter ended April 30, 2026, with net income increasing 29% to $69.4 million and Adjusted EBITDA rising 17% to $164.5 million. The company reported a 7% increase in revenue to $354.6 million and saw total HSA Assets grow 19% to $37.1 billion. HealthEquity also raised its fiscal 2027 guidance and authorized an additional $1.0 billion for its common stock repurchase program, reflecting confidence in its long-term cash-generating power.
HealthEquity: Fiscal Q1 Earnings Snapshot
HealthEquity Inc. (HQY) reported fiscal first-quarter net income of $69.4 million, or 82 cents per share, surpassing Wall Street expectations. Adjusted earnings were $1.24 per share, and revenue reached $354.6 million, also topping analyst forecasts. The company projects full-year earnings between $4.66 and $4.73 per share, with revenue in the range of $1.41 billion to $1.42 billion.
KeyBanc reiterates HealthEquity stock rating ahead of earnings By Investing.com
KeyBanc has reiterated an Overweight rating on HealthEquity (NASDAQ: HQY) with a $125 price target, anticipating the company's first-quarter earnings report. InvestingPro analysis suggests the stock is undervalued, boasting a perfect Piotroski Score and an attractive PEG ratio. The firm believes there will be strong positioning for new members and updated full-year guidance around the earnings release, supported by insights from app data tracking.
HealthEquity, Inc. (HQY) Stock Analysis: Navigating a 28.11% Potential Upside in the Healthcare Sector
HealthEquity, Inc. (HQY) presents a promising investment opportunity in the health information services sector, driven by strong financial metrics and market performance. With a market capitalization of $7.39 billion, analysts project a 28.11% upside from its current trading price of $88.11, setting an average target price of $112.88. The company's robust revenue growth, solid free cash flow, and widespread analyst support underscore its potential for significant gains within a diversified investment portfolio.
(HQY) Risk Channels and Responsive Allocation
This article provides an in-depth analysis of Healthequity Inc. (NYSE: HQY), highlighting a potential shift in near-term positive sentiment, broader weak alignment, and a testing resistance level. It details an exceptional 33.2:1 risk-reward short setup and outlines specific institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) with entry zones, targets, and stop-loss levels. The report also includes a multi-timeframe signal analysis for near-term, mid-term, and long-term horizons, along with AI-generated signals for support and resistance.
Healthequity Inc at JPMorgan Healthcare Conference Transcript
This transcript captures a presentation by Healthequity Inc. executives, including CEO Scott Cutler, at the JPMorgan Healthcare Conference. The company's business is introduced by Scott Cutler, with discussions later involving founder Doctor Steve Nilman and CFO Jim Lucania during the Q&A session. The article lists various past and future earnings call and conference transcripts for HealthEquity.
HealthEquity Is Maintained at Outperform by Barrington Research
Barrington Research has reiterated its Outperform rating for HealthEquity (NASDAQ: HQY). The firm maintains its positive outlook on the company.
A Look at HealthEquity Inc (HQY) After 3.4% Gain -- GF Value $10
HealthEquity Inc (HQY) saw a 3.4% gain, bringing its price to $87.53, while its GF Value is $101.27, indicating it is 13.6% undervalued. The company has a strong GF Score of 92/100, driven by excellent growth and valuation metrics, although its momentum is lower. No insider transactions have been reported in the last three months, suggesting executive stability.
HealthEquity, Inc. (HQY) Stock Analysis: Analysts See Potential 37% Upside
HealthEquity, Inc. (HQY) shows significant investment potential with analysts predicting a 37.37% upside. The company, a leader in health information services, is valued at $6.89 billion and trades near the lower end of its 52-week range. Positive analyst ratings and strong financial health, including substantial free cash flow and revenue growth, support its compelling case for growth-oriented investors.
What HealthEquity (HQY)'s AI Push and Record HSA Growth Focus Means For Shareholders
HealthEquity (HQY) recently presented at a healthcare conference, highlighting its AI-driven platforms and record Health Savings Account (HSA) growth. While these advancements promise efficiency and earnings, investors are weighing the potential for increased margins against risks like technology spending and data security concerns. The company projects significant revenue and earnings growth by 2029, with a fair value estimate suggesting a 37% upside.
